Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Fong Clinical Risk Score (CRS)

The Fong Clinical Risk Score (CRS) predicts the risk of tumor recurrence after hepatic resection for metastatic colorectal cancer.

Evidence-based context for fast calculator use

Purpose:
Fong Clinical Risk Score predicts recurrence after hepatic resection of colorectal liver metastases to guide postoperative surveillance planning.
Population:
patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model
Factors:
Node-positive primary tumor?, Disease-free interval < 12 months?, Number of hepatic tumors > 1?, Largest hepatic tumor > 5 cm?, CEA level > 200 ng/mL?
Reference:
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-318.
HomeFong Clinical Risk Score (CRS)
Pin your most used calculators here by clicking the star in the dropdown.

Fong Clinical Risk Score (CRS)

Clinical Context & Background

The Fong Clinical Risk Score (CRS) predicts the risk of tumor recurrence after hepatic resection for metastatic colorectal cancer. It aids in patient counseling and surveillance planning.
Primary Source EvidenceFong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-318.
Formula Logic
Sum of 5 risk factors (1 point each).

Reference Data

Score5-Year SurvivalRecurrence Risk
060%Low
144%Low-Intermediate
240%Intermediate
320%High
425%High
514%Very High

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Fong Clinical Risk Score (CRS) when fong Clinical Risk Score predicts recurrence after hepatic resection of colorectal liver metastases to guide postoperative surveillance planning.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 through 5.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary site, histology, stage, surgery status, systemic-treatment timing, and disease-specific guideline before applying the result.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer thresholds across colorectal, GIST, gastric, appendiceal, and other peritoneal malignancies.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model

How to apply this result

For a representative case, verify Node-positive primary tumor?, Disease-free interval < 12 months?, Number of hepatic tumors > 1?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

GI, GIST & Peritoneal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Modified Glasgow Prognostic Score (mGPS)Peritoneal Carcinomatosis Index (PCI)NIH GIST Risk (Miettinen)

Frequently Asked Questions

When should Fong Clinical Risk Score (CRS) be used?

Use it for patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model when all required inputs and the intended clinical setting are confirmed.

Can Fong Clinical Risk Score (CRS) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.